FDA 483 - Mylan Laboratories Limited - May 15, 2026
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Mylan Laboratories Limited in Sinnar, India, revealed critical deficiencies in data integrity, quality control, and manufacturing practices. The firm was cited for altering manufacturing records, destroying balance printouts, lacking raw data for QC testing, and failing to adequately control analytical balances. Additionally, the inspection found inadequate investigations into out-of-specification results, poor equipment maintenance, non-compliance with stability testing, and failure to submit a required Field Alert Report after a plant fire.
ID · ec2d5c33-b1bd-414b-b804-7278b844f215